Leidos’ second quarter was marked by strong revenue momentum and a positive market reaction, reflecting solid execution in its core defense and homeland segments. Management highlighted that increased demand for defense technology programs and robust bookings, particularly in the Defense segment, were key contributors to growth. CEO Thomas Bell emphasized, “Defense posted a 2.2 book-to-bill ratio in the second quarter,” underscoring accelerated customer procurement activity and Leidos’ unique position in several emerging defense tech programs. The Health segment faced administrative changes, but management noted proactive cost management and ongoing efficiencies.
Is now the time to buy LDOS? Find out in our full research report (it’s free for active Edge members).
Leidos (LDOS) Q2 CY2026 Highlights:
- Revenue: $4.56 billion vs analyst estimates of $4.44 billion (7.2% year-on-year growth, 2.6% beat)
- Adjusted EPS: $3.26 vs analyst estimates of $2.91 (12.1% beat)
- Adjusted EBITDA: $631 million vs analyst estimates of $594.6 million (13.8% margin, 6.1% beat)
- The company slightly lifted its revenue guidance for the full year to $18.3 billion at the midpoint from $18.2 billion
- Management slightly raised its full-year Adjusted EPS guidance to $12.35 at the midpoint
- Operating Margin: 11.3%, down from 13.4% in the same quarter last year
- Backlog: $48.71 billion at quarter end, up 5.4% year on year
- Market Capitalization: $17.46 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Leidos’s Q2 Earnings Call
- Scott Mikus (Melius Research) questioned the impact of government in-sourcing on MHS GENESIS. CEO Thomas Bell explained that while agencies are exploring insourcing, Leidos’ expertise in system maintenance and enhancement should preserve its role, even if integration work is reduced.
- Matthew Akers (BNP Paribas) asked about margin expectations for the Health segment amid incentive payment suspensions. Bell stated changes are reflected in current guidance and expects quality and efficiency to remain differentiators, with future contract terms still being negotiated.
- Colin Canfield (Cantor) inquired about free cash flow growth levers. CFO Chris Cage highlighted strong Q2 cash performance, lower capital expenditures, and ongoing efficiency projects, noting “the trajectory on free cash flow performance will continue to be strong.”
- Seth Seifman (JPMorgan) pressed for details on bookings cadence and intelligence segment contract mix. Bell signaled increased fixed-price contract interest and pointed to new AI and cyber partnerships as supporting future growth and higher-margin work.
- Tobey Sommer (Truist) asked about Defense segment margin trends as more hardware is integrated. Cage responded that maturing programs are driving higher profitability, with new production contracts expected to reinforce margin expansion.
Catalysts in Upcoming Quarters
In the coming quarters, our team will monitor (1) the pace of major defense award conversions and production ramp-ups, (2) the outcome and structure of the pending VA health contract recompete, and (3) the impact of fixed-price contracting and in-sourcing across key government customers. Execution in emerging technology partnerships and continued cash flow discipline will also be central to tracking Leidos’ progress.
Leidos currently trades at $139.45, up from $118.72 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.